Vita Therapeutics Closes $31M Series B Financing

Vita_Therapeutics_Logo

Vita Therapeutics, a Baltimore, MD-based mobile engineering corporate, raised $31M in Collection B investment.

The spherical was once led by means of Cambrian BioPharma, and Remedy FSHD, with participation from Riptide Ventures, Cedars Sinai, and TEDCO.

The corporate, which has raised a complete of $66m, intends to make use of the budget to advance its pre-clinical program VTA-100 for limb-girdle muscular dystrophy to the hospital, expand its latest program, VTA-120 for the remedy of sufferers with facioscapulohumeral muscular dystrophy, and to additional extend its discovery pipeline.

Led by means of CEO Douglas Falk, Vita Therapeutics is a biotechnology corporate growing mobile therapeutics for the remedy of debilitating neuromuscular sicknesses and cancers. The corporate makes use of brought about stem mobile era to engineer explicit mobile sorts designed to switch the ones which might be faulty in sufferers.

Its present pipeline comprises lead program, VTA-100 for the remedy of LGMD2A, VTA-120 for the remedy of FSHD, and VTA-300 focused on more than one cancers.

  • VTA-100 is these days present process investigational IND-enabling research and is designed to be an autologous remedy that mixes gene correction and brought about iPSC era to assist restore and change muscle cells for other folks with LGMD2A.
  • VTA-120 is designed to be an autologous remedy that mixes gene correction and iPSC era to assist restore and change muscle cells for the remedy of FSHD.
  • VTA-300 is an immunotherapy these days beneath construction that mixes proprietary chimeric antigen receptor (CAR) era and gene modifying to focus on an undisclosed indication.

Long run, the corporate is growing its pipeline of mobile remedies following a twin construction technique starting with autologous-derived cells earlier than transferring to a common hypoimmunogenic mobile line.

Vita Therapeutics is these days running with a lot of companions, together with PanCella, Wyss Institute, and Johns Hopkins College, to advance their scientific systems.

FinSMEs

17/10/2022

Leave a Comment